A sluggish end to fiscal 2019 and weaker-than-expected guidance for the year ahead aren't instilling much confidence in investors.
News & Analysis: Myriad Genetics
Different challenges hit these companies but led to the same result.
The genetic testing company reported fiscal 2019 operating results and told investors that regulators want changes to an important product.
There wasn't much to like with the molecular diagnostics company's latest quarterly update.
MYGN earnings call for the period ending June 30, 2019.
Find out how these stocks stayed higher even after a big plunge in the broader market.
A major insurer agreed to cover one of the company's most important genetic tests.
Wall Street soured on the high-growth industry after first-quarter earnings were reported, but it may have been an overreaction for two stocks.
The genetic testing pioneer lost $500 million in value after reporting fiscal Q3 operating results.
These stocks struggled on a mixed day on Wall Street.